| # | Drug | Count |
|---|---|---|
| 0 | RITUXIMAB | 265 |
| 1 | CYCLOPHOSPHAMIDE | 191 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 191 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 191 |
| 4 | IBRUTINIB | 169 |
| 5 | DOXORUBICIN | 147 |
| 6 | CYTARABINE | 126 |
| 7 | PREDNISONE | 120 |
| 8 | DEXAMETHASONE | 103 |
| 9 | DEXAMETHASONE 1.5 MG | 103 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CAPSICUM OLEORESIN | 1 | 0.0435 |
| 1 | BREXUCABTAGENE AUTOLEUCEL | 36 | 0.0167 |
| 2 | FLUDEOXYGLUCOSE F-18 | 4 | 0.0142 |
| 3 | ZANUBRUTINIB | 34 | 0.0075 |
| 4 | PIRTOBRUTINIB | 7 | 0.0071 |
| 5 | BENDAMUSTINE HYDROCHLORIDE | 58 | 0.0068 |
| 6 | CARMUSTINE | 29 | 0.0061 |
| 7 | BENDAMUSTINE HCL | 56 | 0.0036 |
| 8 | IBRITUMOMAB TIUXETAN | 4 | 0.0026 |
| 9 | TETRACAINE | 1 | 0.0025 |
| # | Drug class | Count |
|---|---|---|
| 0 | CD20-directed Cytolytic Antibody [EPC] | 268 |
| 1 | Kinase Inhibitor [EPC] | 211 |
| 2 | Corticosteroid [EPC] | 201 |
| 3 | Alkylating Drug [EPC] | 194 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 128 |
| 5 | Platinum-based Drug [EPC] | 94 |
| 6 | Topoisomerase Inhibitor [EPC] | 59 |
| 7 | BCL-2 Inhibitor [EPC] | 57 |
| 8 | Proteasome Inhibitor [EPC] | 30 |
| 9 | Thalidomide Analog [EPC] | 30 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Radioactive Diagnostic Agent [EPC] | 4 | 0.0013 |
| 1 | BCL-2 Inhibitor [EPC] | 57 | 0.0009 |
| 2 | CD20-directed Cytolytic Antibody [EPC] | 268 | 0.0008 |
| 3 | Alkylating Drug [EPC] | 194 | 0.0008 |
| 4 | Topoisomerase Inhibitor [EPC] | 59 | 0.0008 |
| 5 | Histone Deacetylase Inhibitor [EPC] | 2 | 0.0005 |
| 6 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 2 | 0.0005 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 128 | 0.0005 |
| 8 | Kinase Inhibitor [EPC] | 211 | 0.0004 |
| 9 | Platinum-based Drug [EPC] | 94 | 0.0003 |